My laboratory uses clinical investigation and applied genomics to reveal mechanisms of human heart failure. This has included establishing a multicenter cohort study of advanced heart failure (Penn Heart Failure Study; PHFS) and a multicenter consortium for human myocardial transcriptomics and eQTL mapping (Myocardial Applied Genomics Network; MAGNet). Notable discoveries include the first demonstration that peripheral blood gene expression provides a clinical biomarker to track cardiac allograft rejection, identification of abnormalities in forkhead signaling and neuregulin signaling in common forms of human heart failure, and discovery of the 1p36 HSPB7/CLCNKA locus as the first bonafide genetic risk factor for non-familial heart failure. In my clinical role I treat patients with advanced heart failure on the inpatient and outpatient heart failure/transplant service.
My clinical focus is evaluation and treatment of advance heart failure including medical therapy, device therapy, investigational therapy, and cardiac transplantation
Liu Y, Morley M, Brandimarto J, Hannenhalli S, Hu Y, Ashley EA, Tang WH, Moravec CS, Margulies KB, Cappola TP, Li M; for the MAGNet consortium: RNA-Seq identifies novel myocardial gene expression signatures of heart failure. Genomics 105(2): 83-89, Feb 2015.
Tampakakis E, Leary PJ, Selby VN, De Marco T, Cappola TP, Felker GM, Russell SD, Kasper EK, Tedford RJ
: The diastolic pulmonary gradient does not predict survival in patients with pulmonary hypertension due to left heart disease. JACC Heart Fail 3(1): 9-16, Jan 2015.
Zamani P, Rawat D, Shiva-Kumar P, Geraci S, Bhuva R, Konda P, Doulias PT, Ischiropoulos H, Townsend RR, Margulies KB, Cappola TP, Poole DC, Chirinos JA
: Effect of inorganic nitrate on exercise capacity in heart failure with preserved ejection fraction. Circulation 131(4): 371-80, Jan 2015.
Zhang R, Zhang Y, Zhang J, An T, Huang Y, Guo X, Januzzi JL, Cappola TP, Yin S, Wang Y, Zhou Q, Zou C, Ji S, Lv R
: The prognostic value of plasma soluble ST2 in hospitalized Chinese patients with heart failure.
PLoS One 9(10): e110976, Oct 2014.
Lu Y, Hannenhalli S, Cappola TP, Putt M: An evaluation of MC Logic and logicFS motivated by a study of
the regulation of gene expression in heart failure. Journal of Applied Statistics 41(9): 1956-1975, Sep 2014.
Vorovich E, French B, Ky B, Goldberg L, Fang JC, Sweitzer NK, Cappola TP
: Biomarker predictors of cardiac hospitalization in chronic heart failure: a recurrent event analysis. J Card Fail 20(8): 569-76, Aug 2014.
Margulies KB, Anstrom K, Hernandez AF, Redfield MM, Shah MR, Braunwald E, Cappola, TP: GLP-1 agonist therapy for advanced heart failure with reduced ejection fraction: design and rationale for the functional impact of GLP-1 for heart failure treatment (FIGHT) study
Circ Heart Fail 7(4): 673-9, Jul 2014.
Basuray A, French B, Ky B, Sweitzer N, Vorovich E, Cappola TP, Fang JC: Heart failure with recovered ejection fraction: clinical description, biomarkers, and outcomes
Circulation 129(23): 2380-7, Jun 2014.
Arking DE, Pulit SL, Crotti L, van der Harst P, Munroe PB, Koopmann TT, Sotoodehnia N, Elizabeth J., Rossin EJ, Morley M, Cappola TP, Olsen JV, Lage K, Schwartz PJ, Kääb S, Chakravarti A, Ackerman MJ, Pfeufer A, de Bakker P, Newton-Cheh C: Genetic association study of QT interval highlights calcium signaling pathways in myocardial repolarization. Nature Genetics 46(8): 826-36, Jun 2014.
Kapoor A, Sekar RB, Hansen NF, Fox-Talbot K, Morley M, Pihur V, Chatterjee S, Brandimarto J, Pfuefer A, Mullikin J, Ross M, Green E, Bentley D, Tomaselli GF, Cappola TP, Arking DE, Halushka MK, Chakravarti A: An enhancer polymorphism at the cardiomyocyte intercalated disc protein NOS1AP locus is a major regulator of the QT interval
Am J Hum Genet 94(6), May 2014.
back to top
Last updated: 03/11/2015
The Trustees of the University of Pennsylvania